T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

Autor:	Anna Sureda-Balari, M. José Terol, Eva Domingo-Domènech, Ana Pilar González Rodriguez, Francisca Hernández Mohedo, Javier Núñez Céspedes, Fátima De La Cruz Vicente, Carmen Martínez Muñoz, M. Elena Amutio Díaz, Raul Córdoba, Antonia Rodríguez Izquierdo, Samuel Romero Domínguez, Javier Briones Meijide, Richard Greil, Miriam Moreno Velázquez, Araceli Rubio, Mariana Bastos Oteiro, Pilar Gómez, Irit Avivi, María Casanova, Raquel Del Campo García, Victor Noriega, José Javier Sánchez Blanco, Ramón. García Sanz
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	HemaSphere, Vol 6, Pp 45-45 (2022)
Druh dokumentu:	article
ISSN:	2572-9241
DOI:	10.1097/01.HS9.0000890960.29449.17
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/5ea6281683dd42bcb50bad7b92c71195 Zobrazit plný text záznamu Plný text View record in DOAJ